8.74
0.11 (1.27%)
| Previous Close | 8.63 |
| Open | 8.82 |
| Volume | 1,632,251 |
| Avg. Volume (3M) | 725,150 |
| Market Cap | 516,310,176 |
| Price / Book | 0.690 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -2.77 |
| Total Debt/Equity (MRQ) | 0.33% |
| Current Ratio (MRQ) | 11.62 |
| Operating Cash Flow (TTM) | -150.21 M |
| Levered Free Cash Flow (TTM) | -87.13 M |
| Return on Assets (TTM) | -25.38% |
| Return on Equity (TTM) | -36.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Cullinan Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | 3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.20 |
|
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.55% |
| % Held by Institutions | 116.27% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 32.00 (BTIG, 266.13%) | Buy |
| Median | 28.00 (220.37%) | |
| Low | 24.00 (HC Wainwright & Co., 174.60%) | Buy |
| Average | 28.00 (220.37%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 6.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Sep 2025 | 24.00 (174.60%) | Buy | 6.53 |
| 21 Aug 2025 | 24.00 (174.60%) | Buy | 7.67 | |
| BTIG | 10 Sep 2025 | 32.00 (266.13%) | Buy | 6.47 |
| Morgan Stanley | 18 Aug 2025 | 28.00 (220.37%) | Buy | 7.95 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 6.97 | - | 1,459,641 | 10,053,743 |
| Aggregate Net Quantity | 1,459,641 | |||
| Aggregate Net Value ($) | 10,053,743 | |||
| Aggregate Avg. Buy ($) | 6.97 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 10 Oct 2025 | Buy (+) | 277,298 | 7.40 | 2,052,005 | |
| LYNX1 CAPITAL MANAGEMENT LP | 09 Oct 2025 | Buy (+) | 626,043 | 7.05 | 4,413,603 | |
| LYNX1 CAPITAL MANAGEMENT LP | 08 Oct 2025 | Buy (+) | 556,300 | 6.45 | 3,588,135 |
| Date | Type | Details |
|---|---|---|
| 12 Oct 2025 | Announcement | Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025 |
| 12 Sep 2025 | Announcement | Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum |
| 09 Sep 2025 | Announcement | Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer |
| 21 Aug 2025 | Announcement | Cullinan Therapeutics to Participate in Upcoming Investor Conferences |
| 07 Aug 2025 | Announcement | Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |